ELISA法检测外周血环氧合酶2活性在亚临床冠状动脉粥样硬化中应用探讨.docVIP

ELISA法检测外周血环氧合酶2活性在亚临床冠状动脉粥样硬化中应用探讨 　　[摘要] 目的：探讨酶联免疫法（ELISA）检测外周血环氧合酶-2（COX-2）活性在亚临床冠状动脉粥样硬化（AS）中的应用价值。方法：应用选择性COX-2抑制剂（塞来昔布）对亚临床冠状动脉粥样硬化进行短期干预，ELISA法检测各分组血浆COX-2水平，并结合临床资料进行分析。结果：亚临床AS组COX-2水平[（10.84±3.11）U/L]，明显高于正常对照组[（6.97±1.25）U/L]（P0.05）；塞来昔布组在接受塞来昔布后COX-2水平显著降低（P0.05），接近正常对照组水平（P＞0.05），与安慰剂组有明显差异（P0.05）。结论：亚临床AS血浆COX-2水平明显升高，ELISA法测定血浆COX-2活性可作为亚临床AS的诊断、预后的参考指标。 　　[关键词] ELISA法，COX-2；选择性COX-2抑制剂；动脉粥样硬化 　　[中图分类号] R543.3 [文献标识码]A[文章编号]1674-4721（2011）01（b）-030-02 　　 　　The application discussion of ELISA to detect PB COX-2 activity on subclinical coronary atherosclerosis 　　LIU Xuhua, ZHU Minghui, GUO Kai 　　(The Peoples Hospital of Zhengzhou City, Henan Province, Zhengzhou450003，China) 　　[Abstract] Objective: To discuss the value of ELISA to detect the application of peripheral blood COX-2 activity on subclinical coronary atherosclerosis. Methods: Used selective COX-2 inhibitors (celecoxib) to perform short-term intervention on sub-clinical coronary atherosclerosis anddetected different groups of plasma COX-2 by ELISA and analyzed with clinical data. Results: The level of subclinical coronary AS group was [(10.84±3.11) U/L], which was obviously higher than that of the normal comparison group[(6.97±1.25) U/L]; The difference between celecoxib group and placebo group was significant (P＜0.05); and the level of COX-2 obviously reduced after receiving celecoxib, no difference compared with the normal group(P＜0.05). Conclusion: COX-2 level is significantly associated with subclinical coronary atherosclerosis(AS), and detecting the activity of plasma COX-2 by ELISA can be used as diagnosis of subclinical coronary atherosclerosis and a reference indicator to prognostic. 　　[Key words] ELISA; COX-2; Selective COX-2 inhibitors; Atheroselerosis 　　 　　环氧合酶-2通过活化的巨噬细胞调节前列腺素（PGE2）的合成，与炎症和动脉粥样硬化的发生有关。研究发现[1-2]COX-2在AS病变处表达，并受多种炎性细胞因子调节，而其代谢产物也具有促进炎症作用，这表明它参与了AS形成和发展的病理过程，而抑制COX-2作为AS新的治疗手段，虽然尚存争议，但已初步在临床应用。本研究应用ELISA法检测各分组血浆COX-2活性，快速简捷，可作为亚临床AS的诊断、预后诊断的参考指标。现报道如下： 　　1